Jack W. Callicutt
2023
In 2023, Jack W. Callicutt earned a total compensation of $561.4K as Chief Financial Officer at Galectin Therapeutics, a 1% decrease compared to previous year.
Compensation breakdown
| Bonus | $110,400 |
|---|---|
| Option Awards | $39,946 |
| Salary | $364,000 |
| Other | $47,073 |
| Total | $561,419 |
Callicutt received $364K in salary, accounting for 65% of the total pay in 2023.
Callicutt also received $110.4K in bonus, $39.9K in option awards and $47.1K in other compensation.
Rankings
In 2023, Jack W. Callicutt's compensation ranked 1,888th out of 2,949 executives tracked by ExecPay. In other words, Callicutt earned more than 36.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,888 out of 2,949 | 36th |
Division Manufacturing | 1,085 out of 1,622 | 33rd |
Major group Chemicals And Allied Products | 675 out of 904 | 25th |
Industry group Drugs | 658 out of 867 | 24th |
Industry Pharmaceutical Preparations | 470 out of 625 | 25th |
Source: SEC filing on December 3, 2024.
Callicutt's colleagues
We found two more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2023.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020